You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameAttapulgite
Accession NumberDB01574
TypeSmall Molecule
GroupsApproved, Vet Approved
DescriptionAttapulgite is a magnesium aluminium phyllosilicate which occurs in a type of clay soil common to the Southeastern United States. When used in medicine, it physically binds to acids and toxic substances in the stomach and digestive tract. For that reason, it has often been used in antidiarrheal medications. Until 2003, it was the active ingredient used in Kaopectate, before that product was reformulated with bismuth subsalicylate.
Structure
Thumb
Synonyms
Activated attapulgite
Aluminium magnesium silicate (attapulgite)
Attapulgite (activated)
Attapulgite, activated
Attapulgite,activated
Attapulgus clay
External IDs Not Available
Product Ingredients Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Children's Kaopectate Sus 600mg/15mlSuspension600 mgOralUpjohn1992-12-312001-07-27Canada
Extra Strength Kaopectate Tablets 750mgTablet750 mgOralJohnson & Johnson Merck Consumer Pharmaceuticals Of Canada1998-04-062005-07-14Canada
Kaopectate Chewable Tab 300mgTablet300 mgOralUpjohn1990-12-312001-07-27Canada
Kaopectate Chewable Tablets 300mgTablet300 mgOralJohnson & Johnson Merck Consumer Pharmaceuticals Of Canada1998-09-182002-07-18Canada
Kaopectate Extra Strength SusSuspension750 mgOralUpjohn1992-12-312001-07-27Canada
Kaopectate Extra Strength Tab 750mgTablet750 mgOralUpjohn1989-12-312001-07-27Canada
Kaopectate Liq 600mg/15mlLiquid600 mgOralUpjohn1989-12-312001-07-27Canada
Kaopectate Tablet - 600mgTablet600 mgOralJohnson & Johnson Merck Consumer Pharmaceuticals Of Canada1998-07-242002-07-18Canada
Kaopectate Tablets 600mgTablet600 mgOralUpjohn1989-12-311996-09-10Canada
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixtures
NameLabellerIngredients
Diban CapAyerst Laboratories
Donnagel-PG CapWyeth Ayerst Canada Inc.
Categories
UNIIU6V729APAM
CAS number12174-11-7
WeightAverage: 412.684
Monoisotopic: 411.8684309
Chemical FormulaAlH9MgO15Si4
InChI KeyIXWIAFSBWGYQOE-UHFFFAOYSA-M
InChI
InChI=1S/Al.Mg.5H2O.10O.4Si/h;;5*1H2;;;;;;;;;;;;;;/q+3;+2;;;;;;10*-2;4*+4/p-1
IUPAC Name
tetrasilicon(4+) ion aluminium(3+) ion magnesium(2+) ion tetrahydrate hydroxide decaoxidandiide
SMILES
[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[Mg++].[Al+3].[Si+4].[Si+4].[Si+4].[Si+4].[O-][H].[H]O[H].[H]O[H].[H]O[H].[H]O[H]
Pharmacology
IndicationWhen used in medicine, it physically binds to acids and toxic substances in the stomach and digestive tract. For that reason, it has often been used in antidiarrheal medications. Attapulgite is an adsorbent.
Structured Indications Not Available
PharmacodynamicsAttapulgite is an adsorptive magnesium aluminium phyllosilicate which binds to toxins, bacteria and water.
Mechanism of actionAttapulgite adsorbs water, toxins and bacteria, contributing to firmer stools, reducing fluid loss from diarrhea.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions Not Available
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General References
  1. Zaid MR, Hasan M, Khan AA: Attapulgite in the treatment of acute diarrhoea: a double-blind placebo-controlled study. J Diarrhoeal Dis Res. 1995 Mar;13(1):44-6. [PubMed:7657965 ]
  2. Nwachukwu CE, Okebe JU: Antimotility agents for chronic diarrhoea in people with HIV/AIDS. Cochrane Database Syst Rev. 2008 Oct 8;(4):CD005644. doi: 10.1002/14651858.CD005644.pub2. [PubMed:18843696 ]
External Links
ATC CodesA07BC54A07BC04
AHFS Codes
  • 56:08.00
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Clinical Trials
Clinical Trials Not Available
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
SuspensionOral600 mg
CapsuleOral
TabletOral300 mg
SuspensionOral750 mg
TabletOral750 mg
LiquidOral600 mg
TabletOral600 mg
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
logP-0.65ChemAxon
pKa (Strongest Acidic)15.7ChemAxon
pKa (Strongest Basic)-1.8ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area25.3 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity3.7 m3·mol-1ChemAxon
Polarizability1.51 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET featuresNot Available
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of inorganic compounds known as post-transition metal hydroxides. These are inorganic compounds in which the largest oxoanion is hydroxide, and in which the heaviest atom not in an oxoanion is a post-transition metal.
KingdomInorganic compounds
Super ClassMixed metal/non-metal compounds
ClassPost-transition metal oxoanionic compounds
Sub ClassPost-transition metal hydroxides
Direct ParentPost-transition metal hydroxides
Alternative Parents
Substituents
  • Post-transition metal hydroxide
  • Inorganic post-transition metal salt
  • Inorganic hydride
  • Inorganic oxide
  • Inorganic salt
  • Inorganic metalloid salt
Molecular FrameworkNot Available
External DescriptorsNot Available
Comments
comments powered by Disqus
Drug created on August 29, 2007 08:48 / Updated on December 21, 2016 09:23